Bill > HB4638

This bill amends the Texas Pharmaceutical Initiative by expanding the governing board from three to five members appointed by the governor, establishing staggered six-year terms with one-third of board members' terms expiring every two years. The bill updates the business plan submission deadline from October 1, 2024, to June 1 of each even-numbered year and adds a new requirement for the board to provide recommendations on best practices and cost savings related to pharmacy benefits. The bill also extends the expiration of the chapter from September 1, 2025, to September 1, 2027. When initially appointing the new five-member board, the governor will designate specific term lengths for each member: two members will serve until February 1, 2027, two until February 1, 2029, and one until February 1, 2031. The bill's provisions include establishing procedures for board governance, outlining the initiative's organizational structure, and detailing potential services such as statewide pharmacy benefit management, prescription drug distribution, and advanced pharmaceutical preparation, including generic drug manufacturing and gene therapies. The bill aims to enhance the state's pharmaceutical services and create a more robust governance structure for the initiative.

Health and Social Services

https://capitol.texas.gov/BillLookup/History.aspx?LegSess=89R&Bill=HB4638